We studied 100 well-characterized E. coli blood isolates from patients with urosepsis for their susceptibility to nalidixic acid, ampicillin and trimethoprim-sulfamethoxazole, according to prevalence of virulence factors, phylogenetic groups and subgroups, PAI II J96 -like domains (determined by physical linkage of cnf1, hly and hra) and PAI I CFT073 -like domains (determined by physical linkage of papGII to the hly locus). Nalidixic acid resistance was associated with a lower prevalence of sfa/foc, K1 antigen, pathogenicity island II J96 -like domains, subgroup B2/I and a shift towards group A.
Introduction
Escherichia coli is a common cause of extraintestinal infections, such as neonatal meningitis, urinary tract infection and bacteraemia. [1] [2] [3] Several virulence factors (VFs), gathered into pathogenicity islands (PAIs) such as PAI I CFT073 and PAI II J96 , enhance the capacity of E. coli to cause systemic infections. 4, 5 Most strains that cause extraintestinal infections belong to phylogenetic group B2 or D, whereas commensal strains belong mostly to group A or B1. [6] [7] [8] Recent studies show an increase in the incidence of E. coli sepsis 9, 10 and in the prevalence of antimicrobial resistance. [11] [12] [13] [14] Few authors have examined the possible relation between antibiotic resistance among invasive isolates and their phylogenetic subgroup distribution or carriage of VFs and PAIs. [15] [16] [17] Here we examined 100 well-characterized E. coli blood isolates from patients with urosepsis for their susceptibility to nalidixic acid, ampicillin and trimethoprim/sulfamethoxazole, according to prevalence of VFs, phylogenetic groups and subgroups, PAI II J96 -like domains (determined by physical linkage of cnf1, hly and hra) and PAI I CFT073 -like domains (determined by physical linkage of papGII to the hly locus). 3 
Materials and methods
The 100 E. coli isolates previously published were recovered by blood culture from 100 consecutive adults with both communityacquired pyelonephritis and bacteraemia. 3, 18 The isolates were characterized by means of PCR phylogenetic grouping, ribotyping and PCR detection of virulence-related genes. 3, 18 Susceptibility to ampicillin, trimethoprim/sulfamethoxazole, nalidixic acid and ciprofloxacin was determined by the disc diffusion method (Bio-Rad), 19 using CLSI interpretative criteria. 20 E. coli 25922 (ATCC) was used as the reference strain.
Statistical methods
P values of <0.05 in Fisher's exact test were considered to denote significant relationships.
Results
The prevalence of antibiotic resistance was as follows: nalidixic acid, 15%; ampicillin, 58%; trimethoprim/sulfamethoxazole, 25%; and ciprofloxacin, 9%. Nalidixic acid susceptibility was associated with phylogenetic group B2 (68% versus 20% of resistant isolates; P = 0.0004), the virulence genes sfa/foc (32% versus 0%; P = 0.009), K1 antigen (23% versus 0%; P = 0.03) and the PAI II J96 -like domain (24% versus 0%; P = 0.035), whereas nalidixic acid resistance was associated with group A (33% versus 7% of susceptible isolates; P = 0.003). Ampicillin and trimethoprim/ sulfamethoxazole susceptibility status did not influence the prevalence of the studied VFs. Ciprofloxacin-resistant isolates were too rare to determine the relationship between fluoroquinolone susceptibility status and VFs. Trimethoprim/ sulfamethoxazole susceptibility was associated with group B2 (68% versus 40%, P = 0.01), whereas trimethoprim/ sulfamethoxazole resistance was associated with group D (48% versus 20%, P = 0.013).
Among the 15 ribotypes (I-XV) identified in our collection of 100 urosepsis isolates, nalidixic acid susceptibility (15 isolates) was associated with subgroup B2/I (P = 0.0036) and showed a borderline relationship with subgroup B2/II (P = 0.06).
Nalidixic-acid-resistant isolates and trimethoprim/ sulfamethoxazole-resistant isolates were significantly associated with subgroup D/VIII, while ampicillin-resistant isolates were significantly associated with subgroup A/VI. Subgroup B2/III strains included three nalidixic-acidsusceptible isolates carrying a PAI II J96 -like domain (isolates P76, P52 and P77) 3 and also one nalidixic-acid-resistant isolate lacking this PAI (isolate P66). 3 No difference in terms of antimicrobial susceptibility and/or VF carriage was found between compromised and non-compromised hosts.
Discussion
The present study shows that nalidixic-acid-resistant urosepsis strains isolated in France are significantly less likely than their susceptible counterparts to harbour sfa/foc (in accordance with Moreno et al.
21
), K1 antigen and PAI II J96 -like domains. Previous 3, 26 All these studies suggest that nalidixicacid-resistant strains are significantly less likely than their susceptible counterparts to harbour PAI II J96 -like domains. PAI II J96 -like domains, such as sfa/foc, are restricted to group B2, 3 and differences in phylogenetic distribution can therefore largely account for the observed differences in the prevalence of VFs between resistant and susceptible urosepsis isolates. 25, 27, 28 We found a lower prevalence of group B2 (specifically subgroup B2/ I) among quinolone-resistant isolates, in accordance with Moreno et al. 21 and Johnson et al., 27 but we also found a higher prevalence of group A strains, in agreement with Horcajada et al. 24 and Moreno et al. 21 Such a relationship could arise from a greater exposure to antibiotics of group A strains belonging to the faecal flora. We found that our subgroup B2/III strains included both nalidixic-acid-susceptible isolates carrying a PAI II J96 -like domain and one nalidixic-acid-resistant isolate lacking PAI II J96 . These results suggest that nalidixic-acid-resistant isolates may be mutants of nalidixic-acid-susceptible strains. The strain lacking PAI II J96 may have lost this PAI in exchange for resistance. Indeed, by activating the SOS response to inhibition of DNA replication, quinolones may contribute to the excision of bacteriophages or PAIs from the bacterial chromosome.
29,30
Recently, Soto et al. 31 found that subinhibitory concentrations of quinolones induced the loss of a PAI containing hly and cnf1. However, recent studies suggest that the loss of virulence genes rarely occurs concomitantly with the acquisition of quinolone resistance and that this phenomenon is therefore unlikely to explain the paucity of VFs in resistant UTI isolates. 28 Indeed, spontaneous 'en bloc' deletion of PAIs can occur in the absence of quinolone exposure, generating mutants with markedly reduced virulence. 5 Another possible explanation is the clonal spread of nalidixicacid-resistant E. coli strains lacking VFs and/or PAIs during antibiotic exposure. However, ribotyping and VF profiling showed marked genetic heterogeneity in our panel: among the 15 nalidixic-acid-resistant isolates, 11 had unique profiles whereas the other four isolates had an identical profile. Thus nalidixic acid resistance in the population examined is not likely due to the spread of a single resistant clone but rather from several independent events. Trimethoprim/sulfamethoxazole resistance was associated with a lower prevalence of highly virulent group B2 strains and with a higher prevalence of moderately virulent group D strains. This latter shift may help to explain why trimethoprim/ sulfamethoxazole resistance was not associated with a marked reduction in inferred virulence, in keeping with Vila 22 but not with Moreno et al.
21
It is unclear how strains with apparently low virulence can cause sepsis not only in compromised hosts but also in non-compromised hosts. It is conceivable that these strains possess unrecognized VFs or that only certain VFs facilitate bacteraemia. Epidemiological and experimental studies suggested that papC, fyuA/irp-2 (encoding the HPI iron-uptake system) and aer were the minimal prerequisite for bacterial passage from a renal focus of infection into the bloodstream.
2,3,32,33 As we tested only urosepsis isolates, all these VFs were present in almost all the strains, and no difference in the prevalence of these latter genes was found between resistant and susceptible isolates.
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